Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Condition:   Head and Neck Cancer Interventions:   Drug: Xevinapant;   Drug: Cisplatin;   Radiation: intensity-modulated radiation therapy (IMRT) Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials